Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy

Eur J Cancer. 2019 Jul:115:24-26. doi: 10.1016/j.ejca.2019.04.011. Epub 2019 May 10.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Immunotherapy
  • Lung Neoplasms*

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab